Navigation Links
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
Date:2/7/2008

BRIDGEWATER, N.J., Feb. 7 /PRNewswire/ -- New data showed that at 48 weeks, significantly more treatment-experienced adults with HIV-1 with documented resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) had an undetectable viral load (defined as less than 50 HIV-1 RNA copies/mL) with INTELENCE (etravirine) tablets plus a background regimen (BR) compared with placebo plus a BR. These findings from two ongoing double-blind, placebo-controlled, randomized Phase 3 studies (DUET-1 and DUET-2) were presented at the 15th Conference on Retroviruses and Opportunistic Infections in Boston.

In the DUET-1 and -2 studies, 60 percent and 61 percent of patients in the INTELENCE arms had a confirmed undetectable viral load at 48 weeks compared with 39 percent and 41 percent of those in the placebo arms, respectively. In each study, this difference was significant [p<0.0001].

INTELENCE, a new NNRTI from Tibotec, received accelerated approval from the U.S. Food and Drug Administration (FDA) on January 18, 2008. It is the first NNRTI to receive approval in almost ten years. INTELENCE received approval based on the 24-week analysis of HIV viral load and CD4+ cell counts from the pooled DUET-1 and -2 studies. The 48-week results will be filed with the FDA for consideration of traditional approval of INTELENCE.

"Etravirine is an important new option for treatment-experienced patients with NNRTI resistance and these data build upon the 24-week data that had previously been available," said Richard Haubrich, M.D., Professor of Medicine, Division of Infectious Diseases, University of California, San Diego, and investigator in the INTELENCE Phase 3 DUET studies.

INTELENCE, in combination with other antiretroviral (ARV) agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication an
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
2. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
3. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
4. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
5. Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
6. Vanda Presents Phase III Iloperidone Efficacy Data
7. Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting
8. TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
11. Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... HARRISBURG, Pa. , Aug. 31, 2015 ... been reversed statewide since Pennsylvania ... the life-saving drug kits, naloxone. Heroin and ... in Pennsylvania , killing more individuals ... 2013, approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... DIEGO , Aug. 31, 2015 Regen ... today development of a novel means of delivering ... acid, RGBP-248, to liver tumors utilizing a clinically ... development overcomes previous hurdles with gene silencing therapeutics ... be delivered throughout the whole body.  By utilizing ...
(Date:8/31/2015)... PRINCETON, N.J. , Aug. 31, 2015  /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today it has ... by the Data Review Committee (DRC) earlier this ... SGX942.  SGX942 is a first-in-class innate defense regulator ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... May 18, 2011 Oclaro, Inc. (NASDAQ: ... communications and laser solutions, today outlined its complete line ... of future products.  As a leading provider of diodes ... leverage its world-class manufacturing operations, technology expertise and packaging ...
... 18, 2011 Cempra Pharmaceuticals Inc. today announced that Prabhavathi ... two upcoming investor conferences in Paris.  Dr. Fernandes will present ... a.m. CET, May 24, at the Hilton Arc de Triomphe. ... at 3:00 p.m. CET, May 24, at the Paris ...
Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2
(Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric ... injury with emphasis on transcranial near-infrared laser phototherapy ”. , As corresponding author ... has been largely untreatable - with mostly palliative treatments only - and now ...
(Date:8/31/2015)... ... ... Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center is celebrating ... surgical and non-surgical disorders of the leg, ankle and foot. He also specializes ... , Dr. Paul Kovatis completed his orthopedic leg, ankle and foot fellowship training at ...
(Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications (DP), ... it has officially launched a new website and company identity ( diablopublications.com) . ... more closely aligned with the company’s strategic vision for growth and expansion over ...
(Date:8/31/2015)... Cokato, MN (PRWEB) , ... August 31, 2015 , ... ... and new product introductions: The Terrace Outdoor Sauna. After months of extensive engineering and ... attractive sauna model built to withstand the elements and is offered at a very ...
(Date:8/31/2015)... ... 2015 , ... Wyoming Medical Center, an acute care hospital ... Documentation Improvement (CDI) and medical coding needs. Based on a proprietary Natural Language ... an enterprise-level coding solution that combines CDI, Coding, Quality and Compliance Auditing modules ...
Breaking Medicine News(10 mins):Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4
... Are Ignoring the Fight Against Cancer, CLEVELAND, ... took the stage for a final debate before ... matters important to the,American public but fell short ... cancer is an issue identified by 62 percent ...
... Clinton Defends Healthcare Plan Built on Extending Customers and ... Revenue of Private Insurance ... Moore,participated in a press conference call today organized by ... from the movie SiCKO, including Reggie Cervantes, a,9/11 rescue ...
... Aflac Incorporated,(NYSE: AFL ) announced today that ... 29th Annual Institutional Investors Conference. President and Chief,Financial ... he is scheduled to make a presentation on ... Incorporated presentation, Mr. Cloninger will discuss the,company,s outlook ...
... of the worlds pre-eminent experts in urogynecology at Oregon Health ... the National Institutes of Health to study the extent of ... , The pelvic floor comprises the muscle group that ... injury, which is caused by damage to pelvic muscles or ...
... Citing a Center for,Medicare and Medicaid Services (CMS) ... 20 percent of national health care spending by,2017, ... statement,urging the House to take up legislation introduced ... (D-Md.) to safeguard Medicare:, "Looking at this ...
... -- Millions of cancer patients take drugs to boost ... anemic after chemotherapy. But a new study by Northwestern ... erythropoiesis-stimulating agents (ESAs), actually raise patients, risk of death, ... , A meta-analysis of 51 trials with 13,613 patients ...
Cached Medicine News:Health News:Democratic Candidates Miss Key Health Issue in Debate 2Health News:Michael Moore Defends 9/11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 2Health News:Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference 2Health News:NIH awards OHSU researcher $1.2 million to determine causes of, risk factors for pelvic floor injury 2Health News:Blunt Cites New CMS Report in Calling for Action on Safeguarding Medicare 2Health News:Drug for anemic cancer patients raises risk of death 2Health News:Drug for anemic cancer patients raises risk of death 3
The COBE 2991 Cell Processor provides reliable, automated cell processing, with the control you need to get reproducible results in your lab. This versatile machine offers users reliability and multi...
The Wallac Multipette is used with 5 mL or 2.5 mL Combitips....
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... lightweight and balanced for smooth, one-handed control. ... comfort, reducing fatigue in even the longest ... physician to easily steer the catheter through ... one finger. Reflexion's auto-lock technology keeps the ...
Medicine Products: